Dual versus monotherapy with bronchodilators in GOLD group B COPD patients according to baseline FEV1 level: a patient-level pooled analysis of phase-3 randomized clinical trials

Table 3 Changes in total SGRQ score from baseline following dual or monotherapy of LABA and/or LAMA

	Intervention	Mean change in total score of SGRQ (SD)	Treatment difference vs. dual (95% CI)	p-value
GOLD III/IV	Dual	− 7.63 (12.09)
	LABA	− 5.51 (12.76)	− 2.12 (− 3.52 to − 0.72)	0.001
	LAMA	− 5.85 (12.84)	− 1.79 (− 2.87 to − 0.70)	< 0.001
GOLD I/II	Dual	− 7.16 (12.49)
	LABA	− 6.83 (12.54)	− 0.33 (− 1.83 to 1.18)	0.868
	LAMA	− 6.04 (12.89)	− 1.12 (− 2.24 to 0.01)	0.048

CI confidence interval, GOLD Global initiative for Chronic Obstructive Lung Disease, LABA long-acting beta-2 agonist, LAMA long-acting muscarinic antagonist, SD standard deviation, SGRQ St. George’s Respiratory Questionnaire